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Abstract  
Purpose: Despite therapeutic advances, survival following relapse for 
neuroblastoma patients remains poor. We investigated clinical and biological 
factors associated with length of progression free and overall survival following 
relapse in UK neuroblastoma patients.  
Methods:  All cases of relapsed neuroblastoma, diagnosed 1990-2010, were 
identified from four Paediatric Oncology principal treatment centres. Kaplan-
Meier and Cox regression analyses were used to calculate post relapse overall 
survival (PROS), post relapse progression free survival (PRPFS) between 
relapse and further progression, and to investigate influencing factors.  
Results: 189 cases were identified from case notes, 159 (84.0%) high risk and 
17 (9.0%), unresectable, MYCN non-amplified (non-MNA) intermediate risk 
(IR).  For high risk patients diagnosed >2000, median PROS was 8.4 months 
(inter quartile range (IQR) = 3.0-17.4) and median PRPFS was 4.7 months 
(IQR=2.1-7.1). For IR, unresectable non-MNA patients, median PROS was 
11.8 months (IQR 9.0-51.6) and 5-year PROS was 24% (95% CI 7%-45). 
MYCN amplified (MNA) disease and bone marrow metastases at diagnosis 
were independently associated with worse PROS for high risk cases. 80% of 
high risk relapses occurred within 2 years of diagnosis compared with 50% of 
unresectable non-MNA IR disease.  
Conclusion:  Patients with relapsed HR neuroblastomas should be treatment 
stratified according to MYCN status and PRPFS should be the primary endpoint 
in early phase clinical trials.  The failure to salvage the majority of IR 
neuroblastoma is concerning, supporting investigation of intensification of 
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upfront treatment regimens in this group to determine whether their use would 
diminish likelihood of relapse. 
Keywords: relapsed neuroblastoma, epidemiology, post relapse progression 
free survival, post relapse overall survival, high risk, intermediate risk  
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Introduction  
Neuroblastoma, the second most common childhood solid tumour, 
accounts for 8% of all childhood (0-14 years) cancers in the UK (Stiller, 2007). 
It is one of the most difficult childhood cancers to cure with UK & Ireland five-
year survival of 64.7% for cases diagnosed during 2005-2007 (Gatta et al, 
2014).   
However, survival remains poor for children diagnosed with high-risk 
disease (50% of all neuroblastoma) (Cohn et al, 2009) defined as stage 4 >1 
year of age, or MYCN amplified (MNA) localised (stage 2 & 3) or MNA infant 
(<12 month) disease, with relapse in >50% of cases (Maris et al, 2007; Maris, 
2010). Relapse also occurs in other risk groups including intermediate risk 
(around 20% of cases at diagnosis) defined as MYCN non-amplified (non-
MNA), unresectable (stage 3) and non-MNA stage 4 <12 months old cases. 
The presence of MNA is a well-established poor prognostic marker in patients 
with neuroblastoma with localized disease and infants <12 months of age (Cohn 
et al, 2004; Maris et al, 2007; Canete et al, 2009). Survival from relapsed high 
risk neuroblastoma is currently less than 10% (London et al, 2011; Park et al, 
2013). The disease control intervals and the patterns of recurrence are 
important for evaluation of new treatment strategies and early phase study 
designs, as they are increasingly being used to define alternative end-points to 
tumour response (Santana et al, 2008; Fox et al, 2014).  
Some recent studies have reported clinical features of relapsed 
neuroblastoma (Garaventa et al, 2009; London et al, 2011; Simon et al, 2011), 
however few report length of post-relapse progression free survival. The 
present study aimed to investigate factors associated with recurrence, survival 
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length following relapse and length of progression free survival in patients with 
neuroblastoma diagnosed and treated at four UK Paediatric Oncology principal 
treatment centres.  This study included information from patient file review on 
post-relapse progression free survival, which is essential for informing the 
design and judging the efficacy of new treatments tested in early phase clinical 
trials.  
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Methods 
Study Patients 
All cases of relapsed and refractory/progressive neuroblastoma 
diagnosed 1990–2010, were identified from four UK Paediatric Oncology 
principal treatment centres (The Royal Victoria Infirmary, Newcastle, Leeds 
Teaching Hospitals NHS Trust, The Royal Manchester Children’s Hospital and 
The Royal Marsden Hospital). Population-based data from three specialist 
registries were used: the Northern Region Young Persons’ Malignant Disease 
Registry (NRYPMDR) (Cotterill et al, 2000), the Yorkshire Specialist Register 
of Cancer in Children and Young People (YSRCCYP) (Feltbower et al, 2004) 
and the Manchester Children’s Tumour Registry (MCTR) (Birch, 1988), and a 
non-population database held at the Royal Marsden Hospital NHS Foundation 
Trust. All cases within the age ranges of the registries were included. 1990 was 
chosen as the start date as from this date onwards combination chemotherapy 
and high dose myeloablative therapy were routinely used to treat high risk 
neuroblastoma (Pritchard et al, 2005; Pearson et al, 2008). Nine patients who 
died within seven days of relapse were excluded as their survival and treatment 
data at relapse would be limited.   
Definition of Relapse  
The International Neuroblastoma Response Classification (INRC) 
criteria were used to define relapse as a  new site of disease or 25% increase 
in tumour size following an initial response (including partial) to treatment, and 
refractory disease as tumours which did not respond to any first, second or third 
line therapies and subsequently progressed (Brodeur et al, 1993).  
Statistical Analysis  
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Table 1 and Supplementary Table S1 show the demographic and clinical 
variables studied at diagnosis and relapse. Post-relapse overall survival time 
(PROS) was the primary end point, defined as time from first 
relapse/progression (including relapsed refractory disease) to death or date of 
last follow-up in survivors. Follow-up was censored at 31st March 2014. Kaplan-
Meier methods were used to calculate estimates of PROS and post-relapse 
progression free survival (PRPFS) which is the time between relapse and 
further relapse/progression (Kaplan & Meier, 1958). Log-rank tests were used 
to compare differences in survival estimates between variables. Cox 
proportional hazards regression analysis was used to investigate risk factors 
that may influence PROS (Cox, 1972). The associations between PROS and 
MYCN amplification, 1p deletion, time interval from diagnosis to relapse and 
age at diagnosis were analysed. Age at diagnosis was categorised into <18 
months, ≥18 months and < 5 years, ≥ 5 years, since 18 months is now used to 
stratify patients at diagnosis and there is evidence that older children have a 
more protracted relapse course (Cohn et al, 2009). Time interval from diagnosis 
to relapse was categorised as <6 months, 6 to <12 months, 12 to <18 months, 
18 to <24 months and ≥24 months to enable comparison with previously 
published studies (London et al, 2011; Simon et al, 2011). Two time periods of 
diagnosis, ≤ 2000 and > 2000, were used to categorise patients as around this 
time treatment for high risk neuroblastoma was intensified (Kohler et al, 2007; 
Pearson et al, 2008; Ladenstein et al, 2010; Kohler et al, 2013). Only models 
that met the Cox proportional hazard assumption are presented (Cox, 1972).  
Subgroup analyses by risk group were carried out for high risk and 
intermediate risk (IR) patients using the International Neuroblastoma Risk 
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Group (INRG) definitions and a comparison of survivors versus non-survivors 
(Cohn et al, 2009). Detailed analysis of unresectable, non-MNA cases was 
undertaken as this group has varied clinical behaviour (Park et al, 2009; Baker 
et al, 2010). Where the total number of cases was low, the 95% Wilson 
confidence intervals for binomial percentages were calculated. Stata version 12 
was used for all analyses, with statistical significance taken to be P<0.05 
(StataCorp, 2011). 
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Results 
189 cases of relapsed neuroblastoma, were identified in this study.  A 
flow diagram showing numbers of patients by risk group is given in Figure 1. 
For all relapsed cases PROS significantly increased after 2000 (P<0.001) 
(Supplementary Figure S1a and Supplementary Figure S1b).  
High risk group (Table 1 & Supplementary Table S1) 
The number of cases analysed for each variable differed depending on 
the completeness of available data. At diagnosis, 90% of cases were treated in 
a clinical trial or per clinical trial protocol (Supplementary Table S2). The overall 
response assessment according to the INRC criteria (Brodeur et al, 1993) at 
the end of first line treatment was: partial response including very good partial 
response for 70/139 (50%) cases and complete response for 30/139 (22%) 
cases. At first relapse, 124/159 (78%) of cases relapsed within 2 years of 
diagnosis and 13/107 (12%) of patients relapsed at the primary site alone. In 
60 patients (38%) in whom levels of urinary catecholamines were recorded at 
diagnosis and relapse, 48 (80%) had raised urinary catecholamines levels at 
both diagnosis and relapse. 
The median PROS time for all high risk cases was 4.5 months (inter-
quartile range (IQR) 1.9–11.4) which was significantly increased for patients 
diagnosed after 2000 versus before (P<0.001) (Figure 2a, Figure 2b,  
Supplementary Figure S2a and Supplementary Figure S2b). Significantly more 
patients diagnosed after 2000, 60/74 (81%), were treated actively at relapse 
compared to those who were given palliative radiotherapy or supportive care 
alone 14/74 (19%); versus 22/64 (44%) ≤2000) (P=0.03). Active treatments at 
relapse included second line chemotherapy, mIBG therapy, or second line 
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chemotherapy followed by other treatments such as radiotherapy, or phase I or 
II clinical trials in 10/138 (7%) cases (Table 2). Figure 3 shows that for cases 
diagnosed after 2000, 6/76 (8%) patients treated by mIBG therapy had a 
median PROS of 12.2 months (IQR = 10.9-26.2 months), 5/76 (7%) patients 
enrolled onto phase I or II trials had a median PROS of 13.5 months (IQR = 
7.7–16.4) and 29/76 (38%) treated by second line chemotherapy had a median 
PROS of 6.6 months (IQR = 2.5-17.5) compared to 1.5 months (IQR = 0.6-2.9) 
for cases treated by supportive care (P=0.01). In contrast, before 2000 only one 
patient had mIGB therapy. For 58 cases, the date of further relapse/progression 
was recorded and for those patients the median PRPFS was 4.5 months (IQR 
2.2–8.7 months); it was 3.9 months (IQR 2.5-8.7 months) for 21 cases 
diagnosed before 2000 and 4.7 months (IQR 2.1-7.1 months) for 37 cases 
diagnosed after 2000 (P=0.54). Treatments received at subsequent 
relapse/progression are given (Supplementary Table S3).    
Cox univariable proportional hazards regression analyses for high risk 
cases showed that PROS time was significantly worse for cases with MNA 
disease (P<0.0001), both MNA and 1p deleted disease (P=0.02), liver 
metastases at diagnosis (P=0.02), and for cases who relapsed within 6 months 
of diagnosis compared to relapses >2 years (P=0.03), while patients >5 years 
old at diagnosis had longer PROS (P=0.02) (Supplementary Table S4). 
However, in multivariable analysis only MNA (adjusted HR=2.06, 95% CI 1.22–
3.46, P=0.007) and bone marrow metastases at diagnosis (adjusted HR=2.33, 
95% CI 1.26–4.29, P=0.007) were independently significantly associated with 
worse PROS (Table 3). Information on MYCN status was unknown for 30% of 
cases, so sensitivity analysis was carried out to include the MYCN unknown 
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cases as an additional category in the model which showed that it did not affect 
the results. MNA disease was significantly associated with worse PROS 
(P<0.001) (Figure 2c and Supplementary Figure 2c). Similar results were 
obtained for PROS for cases diagnosed before (P<0.001) (Figure 2d) or after 
2000 (P=0.02) (Figure 2e).  
Intermediate risk, unresectable, MYCN non-amplified group (Table 1 & 
Supplementary Table S1) 
The number of cases analysed for each variable differed depending on 
the completeness of available data. INPC histology was unfavourable in 13/15 
(87%; 95% CI 62-96%) cases and primary tumour site was abdominal in 14/17 
(82%; 95% CI 59-94%)12/17 (71%; 95% CI 47-87%) were treated in a clinical 
trial at diagnosis or per clinical trial protocol (4 cases in European 
Neuroblastoma Study group Fifth study (ENSG5) (Pearson et al, 2008), 2 cases 
in European High Risk Neuroblastoma Study 1 of SIOP-Europe (HRNBL1) 
(Ladenstein et al, 2010), 2 in unresectable NB2009 (Kohler et al, 2013), 4 in 
ENSG9 (ClinicalTrials.gov identifier: NCT00276731) (Supplementary Table 
S2). At the end of treatment 7/15 (47%; 95% CI 25-70%) cases had achieved 
partial response and 6/15 (40%, 95% CI 20-64%) complete response. The 
median PROS time for this group was 11.8 months (IQR=9.0-51.6) 
(Supplementary Figure S3a and Supplementary Figure S3b).  
Significantly more cases relapsed >2 years from diagnosis 8/17 (47%%; 
95% CI 26-69%) compared to high risk cases 35/159 (22%; 95% CI 16-29) 
(P=0.04). 8/13 (62%, 95% CI 36-82%) relapsed at the primary site.  In 9/17 
patients (53%, 31-74%) in whom levels of urinary catecholamines were 
recorded at diagnosis and relapse, 3/9 (33%, 95% CI 12-65%) had raised 
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urinary catecholamine levels at both diagnosis and relapse.  11/16 patients 
(69%, 95% CI 44-86%) were treated with second line high risk type 
chemotherapy at first relapse (Table 2). A further relapse/progression date and 
treatment were recorded for 8 cases, and for those the median PRPFS was 
10.1 months (IQR=7.8–12.3 months).  5/8 (63%, 95% CI 31-86%) were treated 
with second line chemotherapy and the remainder treated by combined 
chemotherapy and surgery or radiotherapy including mIBG therapy or 
supportive care (Supplementary Table S3).  
Survivors (Supplementary Table S5) 
Only 8% of all relapsed patients in our study survived to the end of the 
study period. 15/16 patients (8%, 95% CI 72-99%) were disease free 5 years 
from first relapse. 4/5 of the high risk survivors and 1/4 of the IR were diagnosed 
>2000. The median follow up time from relapse for survivors was 11 years (IQR 
6.6-16.5).  8/16 (50%, 95% CI 28-72%) patients were aged ≤18 months at 
diagnosis, 5/15 (33%, 95% CI 15-58%) had high risk disease at diagnosis, and 
12/13 (85%, 95% CI 58-96%) were non-MNA. At relapse, 8/14 (57%, 95% CI 
33-79%) survivors were treated with second line chemotherapy, and/or with 
radiotherapy and surgery and 1/14 was treated with chemotherapy and 
autologous stem cell transplant. 
Comparing survivors with non-survivors showed that 27% (95% CI 11-
52%) of survivors had favourable INPC histology compared with 4% (95% CI 
1-8%) of non-survivors (P=0.006), 93% (95% CI 70-99%) of survivors had 
complete or partial overall response at end of treatment compared to 71% (95% 
CI 64-79%) (P=0.04), and 50% relapsed >2 years from diagnosis compared to 
21% (95% CI 15-28) of non-survivors (P=0.01) (Supplementary Table S6). Of 
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the high risk survivors, 3/5 were ≥18 months at diagnosis, 4/5 relapsed after 
initial myeloablative therapy and 1/5 relapsed after surgery.  
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Discussion 
This study was designed to gain knowledge about relapsed 
neuroblastoma from primary sources of information and to reflect the outcome 
of these patients, avoiding the selection bias of clinical trials. It is the first multi-
institutional study to report on PRPFS which is a very useful parameter for 
judging the efficacy of early phase clinical trials. The observed interval between 
relapses is important for early phase trials design as it provides a baseline 
comparator for exploratory studies of new agents in relapsed neuroblastoma, 
where the time interval of PRPFS can be used as a primary endpoint when 
designing exploratory trials (Santana et al, 2008 & Fox et al, 2014).  
 The current study reports the demographics of relapsed neuroblastoma 
cases diagnosed 1990–2010 from four UK Paediatric Oncology principal 
treatment centres treating around 30% of all UK patients in total. PROS time 
remains very poor for both high risk and IR (unresectable, non-MNA) disease. 
The median PROS for high risk cases was 4.5 months with only 7% of relapsed 
cases surviving more than 5 years. However, PROS has significantly increased 
for high risk cases diagnosed after the year 2000 compared to before 2000 from 
2.9 months to 8.4 months, achieving a 5 year survival of 12.7%. This significant 
improvement in PROS after 2000 may be due to more patients being treated 
actively at relapse with second line chemotherapy such as temozolomide, 
topotecan, irinotecan or oral etoposide. All these chemotherapy regimens 
increase the PRPFS, but long-term overall survival remains poor (Rubie et al, 
2006; London et al, 2010; Bagatell et al, 2011; Fox et al, 2014). 
High Risk 
16 
 
In contrast to most previous epidemiological studies of relapsed 
neuroblastoma, our study reports second relapses. The duration from first to 
subsequent relapse is important particularly for early phase clinical trial design. 
For a sub-group of patients, the date of a second event was recorded and the 
median PRPFS time to second event was 4.5 months (IQR=2.2-8.7). This is 
shorter than that reported by Santana and colleagues who found a median 
disease progression free interval of 7.2 months between first and second 
relapse (Santana et al, 2008). This may reflect a difference in treatments given, 
as  very few patients in our cohort were treated on phase I or II clinical trials at 
first or subsequent relapse, partly due to a lack of available applicable trials 
prior to 2000 (Moreno et al, 2013). Recently trials for relapsed neuroblastoma 
have opened across Europe, such as the BEACON study, a randomised phase 
II trial exploring the use of bevacizumab and temozolomide or temozolomide-
irinotecan (ClinicalTrials.gov identifier: NCT02308527). The results of our study 
demonstrating the very poor outcomes following relapse strongly argue for the 
inclusion of patients with high risk relapsed neuroblastoma in randomised 
clinical trials at relapse whenever possible. This study does not identify a 
specific group of patients who are less likely to benefit from further treatment at 
relapse.    
Our results for PROS concur with those published using data from the 
INRG database (2,226 relapsed cases), diagnosed 1990 – 2002, where 5 year 
PROS for stage 4 cases, >18 months with non-MNA disease was 8%, and only 
4% for stage 4 with MNA disease (London et al, 2011). Around 55/189 (29%) 
cases from the present study may overlap with the INRG database. A study 
from the Italian neuroblastoma registry reported 10 year PROS for stage 4 
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disease at diagnosis was 1.5% following progression and 2% following relapse 
(Garaventa et al, 2009). Analysis of relapsed high risk neuroblastoma patients 
from German trials diagnosed 1990-2007, treated with second-line 
chemotherapy at relapse, found 3-year PROS was 9.6% (Simon et al, 2011). 
Several prognostic factors are used in risk stratification for 
neuroblastoma at diagnosis including age at diagnosis, MNA, presence of 
segmental chromosomal aberrations, metastatic disease and tumour histology 
(George et al, 2001). These factors may also be important in determining 
response to treatments at relapse. Age >5 years at diagnosis had a longer 
PROS consistent with studies showing that older children have a more 
protracted relapse course (Cohn et al, 2009). We also found worse PROS in 
high risk cases with MYCN amplification as previously reported (London et al, 
2011; Garaventa et al, 2009; Simon et al, 2011; Lau et al, 2004), and with both 
MNA and chromosome 1p deletion at diagnosis. Chromosome 1p deletion has 
been shown to be associated with shorter median PROS (London et al, 2011; 
Lau et al, 2004), poorer event free survival from diagnosis (EFS) (Maris et al, 
2001), and to be strongly related to high risk features (Attiyeh et al, 2005).  Both 
1p deletion and 11q loss were independently associated with shorter PRPFS in 
patients with low and IR disease (Attiyeh et al, 2005). However, in the present 
study insufficient data on 11q or other segmental chromosomal abnormalities 
precluded formal analysis. Interestingly, liver metastases at diagnosis were also 
associated with shorter PROS in our study. In previous studies liver metastases 
were associated with MNA and had a worse prognosis in older children (DuBois 
et al, 1999), unlike infants with non-MNA disease (Kushner et al, 2006). 90% of 
all relapsed cases we studied had primary tumours arising in abdominal sites 
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and only 8% had thoracic or neck tumours. This is in-keeping with other studies 
reporting that adrenal tumours are associated with unfavourable clinical and 
biological characteristics and therefore worse EFS in contrast to thoracic 
tumours which are associated with favourable characteristics and better EFS 
(Sung et al, 2009; Vo et al, 2014). However, we acknowledge the small 
numbers of cases involved in this study and the missing data in some of the 
variables means some results should be interpreted with caution.   
The duration from diagnosis to first relapse has been shown to be a 
prognostic factor for PROS (London et al, 2011; Garaventa et al, 2009; Lau et 
al, 2004). Around 80% of high risk cases in our study relapsed within 2 years 
from diagnosis, and PROS was significantly shorter when relapse occurred 
within 6 months of diagnosis. Lau and colleagues found that patients who 
relapsed either within 6 months from diagnosis or 6 months from stem cell 
transplant had shorter median PROS (Lau et al, 2004). Other studies however, 
reported recurrence within 6 – 24 months from diagnosis implied worse PROS 
(London et al, 2011; Simon et al, 2011).  These differences may be due to 
patient heterogeneity; some studies included only high risk cases (Simon et al, 
2011), whereas others included all relapsed neuroblastoma (London et al, 
2011), or different definitions of relapse.  
The role of urinary catecholamines as a reliable marker for monitoring 
neuroblastoma relapse is controversial (Simon et al, 2003). They may be 
negative due to small tumour burden at relapse or decreased production in 
some previously treated neuroblastomas. In the present study, urinary 
catecholamines were raised at relapse in 80% of patients who had raised 
catecholamines at diagnosis, but were only measured in 46% of patients at 
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relapse. The current study suggests that raised urinary catecholamines are 
helpful as a confirmatory indicator and a tumour marker of response (Kushner 
et al, 2009).  
Intermediate Risk  
IR disease comprised 13% of relapsed neuroblastomas in our study, 4% 
who were IR stage 4, non-MNA <12 months old were not further analysed as 
this subgroup is usually salvageable at relapse (Maris et al, 2007; De Bernardi 
et al, 2009). However, 9% were IR, unresectable, non-MNA with mostly 
unfavourable INPC histology. The prognostic value of pathology in this group 
was confirmed in a recent SIOPEN study (Kohler et al, 2013). Analysis of stage 
3 data from the INRG database showed that patients >18 months with 
undifferentiated INPC histology and elevated levels of serum ferritin had worse 
overall survival and EFS (Meany et al, 2014). In the absence of MYCN 
amplification other genetic markers in this group may be important risk factors, 
such as tumour cell ploidy (Baker et al, 2010; Bagatell et al, 2005), 11q 
aberrations (Attiyeh et al,  2005; Meany et al,  2014) or other segmental 
chromosomal abnormalities (Defferrari et al, 2015). The management of this 
group of patients remains controversial, those with unfavourable histological or 
biological features are treated with intensive multimodality therapy including 
myeloablative therapy in the US (Baker et al, 2010), but not in the UK or Europe. 
However, in the present study 6/17 patients (35%; 95% CI 17-59%) were 
treated in high risk protocols (ENSG5 and HRNBL1) at the physician’s 
discretion due to patient age and/or unknown MYCN status. Almost 50% of IR, 
unresectable, non-MNA neuroblastoma relapsed >2 years from diagnosis 
including 5/17 (29%; 95% CI 13-53%) patients who had local radiotherapy as 
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part of their frontline treatment at diagnosis.  Salvage therapies at relapse failed 
in 75% of cases, suggesting the need for intensification of upfront treatment 
regimens for cases with unfavourable histology at diagnosis (Kohler et al, 
2013), to determine whether their use would diminish the likelihood of relapse. 
 
Conclusion 
In conclusion, this study showed that the PROS for neuroblastoma 
patients has increased but long term survival remains poor. 80% of high risk 
relapses occur within 2 years from diagnosis, in contrast to only 50% of IR 
unresectable, non-MNA neuroblastoma, and although this latter group 
comprise <10% of all relapsed neuroblastoma, the failure to salvage these 
patients in over 75% of cases, even when given high-risk type treatment at 
relapse, is concerning. Since MNA disease has a worse OS as highlighted by 
previous studies, our study underscores the need for early phase clinical trial 
data to be analysed according to MYCN status. Finally, more patients need to 
be recruited to early phase studies where PRPFS should be considered as the 
primary endpoint in study design, especially if cytostatic novel therapies are 
given.  
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Table 1: Patient characteristics at relapse for all cases of relapsed neuroblastoma, high risk cases, and intermediate risk, stage 3, 
unresectable, non-MNA cases. 
 
Table 1:Patient characteristics for all cases of relapsed neuroblastoma, high risk cases and intermediate risk, stage 3, unresectable, non-MNA 
cases 
 All relapsed neuroblastoma   
N=189 
N (%, 95% CI) α 
High risk relapsed  
Neuroblastoma N=159 (84.1%) 
N (%, 95% CI) α  
Intermediate risk (unresectable 
MYCN non-amplified)  
 N=17 (9.0%)  
N (%, 95% CI) β  
P – value** (high vs 
intermediate risk groups) 
Time from diagnosis to relapse      
  Mean 
  Median  
  Inter-quartile range  
  Range  
18.1 months 
14.7 months  
9.2 – 22.1 months 
1.3 – 96.2 months 
17.6 months  
14.6 months  
9.3 – 21.5 months 
1.3 – 96.2 months 
28.8 months 
22.1 months 
10.3 – 39.1 months 
4.0 – 68.5 months 
 
 
0.03 
Time from diagnosis to relapse 
groups 
    
  < 6 months  
  6 – 12 months  
 12 – 18 months  
 18 – 24 months  
  >24 months 
32 (16.9, 11.9-23.1) 
38 (20.1, 14.6-26.5) 
43 (22.8, 17.0-29.3) 
32 (16.9, 11.9-23.1) 
44 (23.3, 17.5-30.0) 
24 (15.1, 9.9-21.6) 
32 (20.1, 14.2-27.2) 
40 (25.2, 18.6-32.6) 
28 (17.9, 12.0-24.4) 
35 (22.0, 15.8-29.3) 
1 (5.8, 1.0-27.0) 
4 (23.5, 9.6-47.3) 
2 (11.8, 3.3-34.3) 
2 (11.8, 3.3-34.3) 
8 (47.1, 26.2-69.0) 
 
0.23 
Site of relapse N = 132 (69.8)* N = 107 (67.3)* N = 13 (76.5)*  
 Primary 
 Metastases  
 Missing 
30 (22.7, 15.9-30.8) 
102 (77.3, 69.2-84.1)  
57 (30.2) b 
13 (12.2, 6.6-19.9) 
94 (87.8, 80.1-93.4) 
52 (32.7) b 
8 (61.5, 35.5-82.3) 
5 (38.5, 17.7-64.5) 
4 (23.5) b 
 
<0.001 
Bone metastases at relapse N = 170 (89.9)* N = 142 (75.1)* 15 (88.2)*  
  No 
  Yes 
  Missing 
87 (51.2, 43.4-58.9) 
83 (48.8, 41.1-56.6) 
19 (10.1) b 
70 (49.3, 40.8-57.8) 
72 (50.7, 42.2-59.2) 
17 (24.9) b 
9 (60.0, 35.7-80.2) 
6 (40.0, 19.8-64.3) 
2 (11.8) b 
 
0.43 
Bone marrow metastasis at 
relapse 
N = 140 (74.1)* N = 116 (73.0)* N = 13 (76.5)*  
 No 
 Yes 
 Missing 
75 (53.6, 45.0-62.0) 
65 (46.4, 38.0-55.0) 
49 (25.9) b 
58 (50.0, 40.6-59.4) 
58 (50.0, 40.6-59.4) 
43 (27.0) b 
9 (69.2, 42.4-87.3) 
4 (30.8, 12.7-57.6) 
4 (23.5) b 
 
0.24 
Urinary catecholamine levels at 
relapse 
N = 87 (46.0)* N = 73 (45.9)* N = 9 (52.9)*  
 Normal  
 Elevated 
20 (23.0, 14.6-33.2) 
67 (77.0, 66.8-85.4) 
14 (19.2, 10.9-30.1) 
59 (80.8, 55.1-77.7) 
6 (66.7, 35.4-87.9) 
3 (33.3, 12.1-64-6) 
 
0.006 
28 
 
 Missing 102 (54.0) b 86 (54.1) b 8 (47.1) b 
Status      
 Alive  
 Dead  
 Lost to follow-up 
16 (8.5, 4.9-13.4) 
166 (87.8, 82.3-92.1) 
7 (3.7, 1.5-7.5) 
5 (3.1, 1.0-7.2) 
148 (93.1, 88.0-96.5) 
6 (3.8, 1.4-8.0) 
4 (23.5, 9.6-47.3) 
13 (76.5, 52.7-90.4) 
     -  
 
0.001 
 
* Percent of the total number of cases. 
** Chi-squared test and the Fisher’s exact test (where numbers were less than 5) were used to compare between high and intermediate risk group 
characteristics. α 95% CI were calculated for percentages using the asymptotic method.  
b Percent with missing data. β 95% CI for proportions were calculated using the Wilson score method.  
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Table 2: Treatment received at first relapse for all relapsed neuroblastoma cases, high risk cases and intermediate risk, 
stage 3, unresectable, non-MNA neuroblastoma.    
 
 
 
* Second line chemotherapy includes vincristine, temozolamide, irinotecan, topotecan vincristine-doxorubicin or oral etoposide.  
** Combination of chemotherapy, surgery, radiotherapy and miBG therapy.  
  
Table 2: Treatment received at first relapse for all relapsed neuroblastoma cases, high risk cases and intermediate risk, stage 3, 
unresectable, non-MNA neuroblastoma.    
 
Treatment All relapsed cases  
N (%) 
High Risk 
N (%) 
Intermediate risk 
N (%) 
 Diagnosed ≤ 
2000 
Diagnosed  
> 2000 
Total Diagnosed 
≤ 2000 
Diagnosed > 
2000 
Total  Diagnosed 
≤ 2000 
Diagnosed  
> 2000 
Total  
Second line Chemotherapy*  29 (36.3) 33 (38.4) 62 (37.4) 22 (34.4) 29 (39.2) 51 (37.0) 2 (22.2) 1 (14.3) 3 (18.8) 
Combination of treatments** 15 (118.8) 17 (19.8) 32 (19.3) 10 (15.6) 12 (16.20 22 (15.9) 4 (44.4) 4 (57.1) 8 (50.0) 
mIBG Therapy  1 (1.3) 6 (7.0) 7 (4.2) 1 (1.6) 6 (8.1) 7 (5.1) 0 (0.0) 0 (0.0) 0 (0.0) 
Other (e.g. Surgery or 
radiotherapy) 
7 (8.8) 10 (11.6) 17 (10.2) 4 (6.3) 8 (10.8) 12 (8.7) 2 (22.2) 2 ( 28.6) 4 (25.0) 
Phase I or II trials 5 (6.3) 5 (5.8) 10 (6.0) 5 (7.8) 5 (6.8) 10 (7.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Palliative radiotherapy  10 (12.5) 6 (7.0) 16 (9.6) 10 (15.6) 6 (8.1) 16 (11.6) 0 (0.0) 0 (0.0) 0 (0.0) 
Supportive care 13 (16.3) 9 (10.5) 22 (13.3) 12 (18.8) 8 (10.8) 20 (14.5) 1 (11.1) 0 (0.0) 1 (6.3) 
Total  80 (100) 86 (100) 166 (100) 64 (100) 74 (100) 138 (100) 9 (100) 7 (100) 16 (100) 
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Table 3: Results of multivariable analysis for post-relapse overall 
survival for high risk cases. 
 
Table 3: Results of multivariable analysis for post-relapse overall survival for 
high risk cases 
Factor N (%) Hazard ratio (95% CI) P-value  
Age at diagnosis    
 ≤ 5 years 
 > 5 years  
126 (79.3) 
33 (20.7) 
1 
0.77 (0.44 – 1.34) 
 
0.35 
Bone marrow metastases at diagnosis     
  No 
  Yes     
26 (17.8) 
120 (82.2) 
1 
2.33 (1.26 – 4.29) 
 
0.007 
Liver metastases at diagnosis     
  No   
  Yes 
122 (87.8) 
17 (12.2) 
1 
1.44 (0.73 – 2.83) 
 
0.29 
MYCN  disease    
  Not amplified 
  Amplified  
67 (57.8) 
49 (42.2) 
1 
2.06 (1.22 – 3.46) 
 
0.007 
Time from diagnosis to relapse     
>24 months  
 18 – 24 months  
  12 – 18 months  
  6 – 12 months  
  < 6 months  
35 (22.0) 
28 (17.9) 
40 (25.2) 
32 (20.1) 
24 (15.1) 
1 
1.18 (0.58 – 2.40) 
1.21 (0.65 – 2.24) 
1.22 (0.65 – 2.31) 
1.52 (0.76 – 3.01) 
 
0.65 
0.54 
0.54 
0.24 
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Supplementary Table S1: Patient characteristics for all cases of relapsed neuroblastoma, high risk cases, and intermediate risk, 
stage 3, unresectable, non-MNA cases. 
 
Table 1:Patient characteristics for all cases of relapsed neuroblastoma, high risk cases and intermediate risk, stage 3, unresectable, non-MNA 
cases 
 All relapsed neuroblastoma   
N=189 
N (%, 95% CI) α 
High risk relapsed  
Neuroblastoma N=159 (84.1%) 
N (%, 95% CI) α  
Intermediate risk (unresectable 
MYCN non-amplified)  
 N=17 (9.0%)  
N (%, 95% CI) β  
P – value** (high vs 
intermediate risk groups) 
Gender 
Male 
Female      
109 (57.7, 50.2-64.8) 
80 (42.3, 35.2-49.7) 
92 (57.9, 49.8-65.6) 
67 (42.1, 34.4-50.2) 
6 (35.3, 17.3-58.7) 
11 (64.7, 41.3-82.7) 
0.08 
 
Age at diagnosis (years) 
  Mean  
  Median  
  Range  
  Inter-quartile range 
≤ 1 year  
4.1 
2.96 
0 – 19 
2.0 – 4.6 
N = 14 
4.1 
3.0 
0 – 19 
2.1 – 4.8 
N = 3 
5.5 
3.9 
0-15 
2.9 – 5.3 
N = 1  
 
0.09 
Age groups     
  <18 months  
  ≥18 months   
28 (14.8, 10.1-20.7) 
161 (85.2, 79.3-89.9) 
17 (10.7, 6.4-16.6) 
142 (89.3, 83.4-93.6) 
1 (5.9, 1.0-27.0) 
16 (94.1, 73.0-99..0) 
 
0.52 
Stage at diagnosis N =185 (97.9)* N=158 (99.4)*   
  Stage 1, 2, 4s 
  Stage 3 
  Stage 4  
  Missing   
5 (2.7, 0.9-6.2) 
20 (10.8, 6.7-16.2) 
160 (86.5, 80.7-91.1) 
4 (2.1)b 
2 (1.3, 0.2-4.5) 
3 (1.9, 0.4-5.4) 
153 (98.1, 92.7-99.0) 
1 (0.6) b 
 
 
- 
 
 
- 
INPC histologya N = 153 (81.0)* N = 129 (81.1)* N = 15 (88.2)*  
  Unfavourable  
  Favourable  
  Missing 
144 (94.1, 89.1-97.3) 
9 (5.9, 2.7-10.9) 
36 (19.0) b 
124 (96.1, 91.2-98.7) 
5 (3.9, 1.3-8.8) 
30 (18.9) b 
13 (86.7, 62.1-96.2) 
2 (13.3, 3.7-37.9) 
2 (11.8) 
 
0.16 
Site of primary tumour   N = 186 (98.4)* N = 156 (98.1)* N = 17 (100.0)  
 Abdominal (includes adrenal  
 and retroperitoneal) 
 Thoracic, spinal and cervical 
 Other 
 Missing  
 
167 (89.8, 84.5-93.7) 
14 (7.5, 4.2-12.3) 
 5 (2.7, 0.8-6.2) 
3 (1.6) b 
 
143 (91.6, 86.2-95.5) 
9 (5.7, 2.7-10.7) 
4 (2.6, 0.7-6.4) 
3 (1.9) b 
 
14 (82.4, 59.0-93.8) 
3 (17.7, 6.2-41.0) 
0 (0.0) 
- 
 
0.14 
32 
 
Lymph node metastasis at 
diagnosis  
N = 169 (89.4) N =142 (89.3) N = 17 (100)  
 No  
 Yes  
 Missing 
95 (56.2, 48.3-63.8) 
74 (43.8, 36.2-51.6) 
30 (10.6) b 
74 (52.1, 43.6-60.6) 
68 (47.9, 39.4-56.4) 
17 (10.7) b 
12 (70.6, 46.9-86.7)  
5 (29.4, 13.3-53.1) 
- 
 
0.15 
Bone metastasis at diagnosis N = 173 (91.5)* N = 146 (91.8) N = 17 (100)  
 No  
 Yes   
 Missing 
60 (34.5, 27.6-42.3) 
114 (65.5, 58.3-72.9) 
16 (8.5) b 
36 (24.7, 17.9-32.5) 
110 (75.3, 67.5-82.1) 
13 (8.2) b 
17 (100, --) 
0 (0.0, --) 
- 
 
- 
 
Bone marrow metastasis at 
diagnosis 
N = 173 (91.5)* 
 
N = 146 (91.8) 
 
N = 17 (100) 
 
 
 No  
 Yes  
 Missing 
51 (29.5, 22.8-36.9) 
122 (70.5, 63.1-77.2) 
16 (8.5)b 
26 (17.8, 12.0-25.0) 
120 (82.2, 75.0-88.0) 
13 (8.2) b 
17 (100.0, --) 
0 (0.0, --) 
- 
 
- 
Liver metastasis at diagnosis  N = 166 (87.8)* N = 166 (87.8)* N = 17 (100)  
 No  
 Yes  
 Missing 
147 (88.5, 82.7-93.0) 
19 (11.5, 7.0-17.3) 
23 (12.2) b 
122 (87.8, 66.1-80.0) 
17 (12.2, 6.1-15.9) 
20 (12.6) b 
17 (100, --) 
0 (0.0, --) 
- 
 
- 
Urinary catecholamine levels at 
diagnosis 
N = 137 (72.5)* N = 116 (73.0)* N = 13 (76.5)*  
 Normal  
 Elevated  
 Missing 
7 (5.1, 2.1-10.2) 
130 (68.8, 89.8-97.9) 
52 (27.5) b 
3 (2.6, 0.5-7.4) 
113 (97.4, 92.6-99.5) 
43 (27.0) b 
2 (15.4, 4.3-42.2) 
11 (84.6, 57.8-95.7) 
4 (23.5) b 
 
0.12 
MYCN status N = 134 (70.9)* N = 116 (73.0)* N = 10 (58.8)*  
  Amplified  
  Not amplified, MYCN  gain  
  Not amplified 
  Missing 
49 (36.6, 28.4-45.3) 
7 (5.2, 2.1-10.5) 
78 (58.2, 49.4-66.7) 
55 (29.1) b 
49 (42.2, 33.1-51.8) 
3 (2.6, 0.5-7.4) 
64 (55.2, 45.7-64.4) 
43 (27.0) b 
- 
2 (20.0, 5.7-51.0) 
8 (80.0, 49.0-94.3) 
7 (41.2) b 
 
- 
1p status N = 65 (34.4)* N= 57 (35.8)* N=3 (15.0)*  
  1p deleted 
  1p normal     
  Missing 
37 (56.9, 44.0-69.2) 
28 (43.1, 30.8-56.0) 
124 (65.6) b 
35 (61.4, 47.6-74.0) 
22 (38.6, 26.0-52.4) 
102 (64.2) b 
 
3 (100.0, 43.9-100) 
14 (85.0) b 
 
- 
MYCN  and 1p N = 62 (32.8)* N = 54 (34.0)*   
Non-MNA and 1p normal 
MNA and 1p normal 
Non-MNA and 1p deleted 
MNA and 1p deleted  
Missing 
23 (37.1, 25.2-50.3) 
3 (4.8, 1.0-13.5) 
7 (11.3, 4.7-21.9) 
29 (46.7, 34.0-60.0) 
127 (67.2) 
17 (31.5, 19.5-45.6) 
3 (5.6, 1.2-15.4) 
5 (9.3, 3.1-20.3) 
29 (53.7, 39.6-67.4) 
105 (66.0) 
 
-  
 
- 
Year of diagnosis      
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≤ 2000 
>2000 
100 (52.9, 45.5-60.2) 
89 (47.14, 39.8-54.5) 
82 (51.6, 43.5-59.6) 
77 (48.4, 40.4-56.5) 
10 (58.8, 41.3-82.7) 
7 (41.2, 21.6-64.0) 
 
0.57 
Overall response at end of 
treatment  
N = 166 (87.8)* N = 139 (87.4)* 15 (88.2)*  
 Stable disease  
 Mixed response  
 Partial response  
 Complete response  
 Progressive disease  
 Missing 
7 (4.2, 1.7-8.5) 
12 (7.2, 3.8-12.3) 
82 (49.4, 41.6-57.3) 
40 (24.1, 17.8-31.3) 
25 (15.1, 10.0-21.4) 
23 (12.2) 
5 (3.6, 1.2-8.2) 
12 (8.6, 4.5-14.6) 
70 (50.4, 41.8-58.9) 
30 (21.6, 15.1-29.4) 
22 (15.8, 10.2-23.0) 
20 (12.6) 
1 (6.7, 1.2-29.8) 
0 (0.0, 0-20.4) 
7 (46.7, 24.8-70.0) 
6 (40.0, 19.8-64.3) 
1 (6.7, 1.2-29.8) 
2 (11.8) 
 
0.36 
 
 
a International Neuroblastoma Pathology Classification (Shimada et al, 1999)49 
* Percent of the total number of cases. 
** Chi-squared test and the Fisher’s exact test (where numbers were less than 5) were used to compare between high and intermediate risk group 
characteristics. α 95% CI were calculated for percentages using the asymptotic method.  
b Percent with missing data. β 95% CI for proportions were calculated using the Wilson score method.  
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Supplementary Table S2: Treatment received at diagnosis for all relapsed neuroblastoma cases, high risk cases and for intermediate 
risk, unresectable, non-MNA neuroblastoma.   
 
a European Neuroblastoma Study group Fifth study (ENSG5) (Pearson et al, 2008)  
b N7 Protocol (Kushner) (Kohler et al, 2007) 
c European High Risk Neuroblastoma Study 1 of SIOP-Europe (HRNBL1) (Ladenstein et al, 2010) 
d ENSG9 (ClinicalTrials.gov identifier: NCT00276731) 
* Other trials include infant neuroblastoma study, MIBG2, or unknown. ** Other treatments were chemotherapy, chemotherapy and surgery, 
chemotherapy and surgery and radiotherapy, or chemotherapy and surgery and radiotherapy and SCT. Chemotherapy was usually 
OPEC/OJEC, CADO, topotecan, TVD, carboplatin-etoposide, cyclophosphamide, vincristine.  
α Five cases diagnosed in 1990 had no available files.   
Supplementary Table S1: Treatment received at diagnosis for all relapsed neuroblastoma cases, high risk cases and for intermediate risk, 
unresectable, non-MNA neuroblastoma.   
 
Treatment All relapsed cases 
N (%) 
High Risk 
N (%) 
Intermediate Risk 
N (%) 
 Diagnosed 
≤ 2000 
Diagnosed 
> 2000 
Total Diagnosed 
≤ 2000 
Diagnosed  
> 2000 
Total Diagnose
d ≤ 2000 
Diagnosed 
> 2000 
Total 
ENSG5 triala 56 (58.9) 0 (0.0) 56 (30.4) 50 (64.9) 0 (0.0) 50 (32.5) 4 (40.0) 0 (0.0) 4 (23.5) 
ENSG5 protocol 7 (7.4) 2 (2.2) 9 (4.9) 7 (9.1) 2 (2.6) 9 (5.8) 0 (0.0) 0 (0.0) 0 (0.0) 
Kushner trialb 4 (4.2) 4 (4.5) 8 (4.3) 4 (5.2) 4 (5.2) 8 (5.2) 0 (0.0) 0 (0.0) 0 (0.0) 
HRNBL1 trialc 0 (0.0) 56 (62.9) 56 (30.4) 0 (0.0) 53 (68.8) 53 (34.4) 0 (0.0) 2 (28.6) 2 (11.8) 
HRNBL1 protocol 3 (3.2) 9 (10.1) 12 (6.5) 3 (3.9) 9 (11.7) 12 (7.8) 0 (0.0) 0 (0.0) 0 (0.0) 
ENSG9d 2 (2.1) 2 (2.2) 4 (2.2) n/a n/a n/a 2 (20.0) 2 (28.6) 4 (23.5) 
Other trials*  10 (10.5) 5 (5.6) 15 (8.2) 6 (7.8) 3 (3.9) 9 (5.8) 1 (10.0) 1 (14.3) 2 (11.8) 
Other treatments ** 13 (13.7) 11 (12.4) 24 (13.0) 7 (9.1) 6 (7.8) 13 (8.4) 3 (30.0) 2 (28.6) 5 (29.4) 
Total   95 (100) α 89 (100) 184 (100) α 77 (100)α 77 (100) 154 (100) α 10 (100) 7 (100) 17 (100) 
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Supplementary Table S3: Treatment received at 2nd and subsequent relapse for all relapsed neuroblastoma cases, high risk 
cases and for intermediate risk, unresectable, non-MNA neuroblastoma.   
 
* Second line chemotherapy includes vincristine, temozolamide, irinotecan, topotecan vincristine-doxorubicin or oral etoposide.  
** Combination of treatments includme chemotherapy and surgery or radiotherapy.  
Supplementary Table S2: Treatment received at 2nd and subsequent relapse for all relapsed neuroblastoma cases, high risk cases 
and for intermediate risk, unresectable, non-MNA neuroblastoma.   
 
Treatment All relapsed cases  
N (%) 
High Risk 
N (%) 
Intermediate risk 
N (%) 
 Diagnosed 
≤ 2000 
Diagnosed 
> 2000 
Total Diagnosed 
≤ 2000 
Diagnosed 
> 2000 
Total Diagnosed 
≤ 2000 
Diagnosed > 
2000 
Total 
Second line Chemotherapy* 10 (34.5) 21 (42.0) 31 (39.2) 8 (34.8) 18 (43.9) 26 (40.6) 2 (100.0) 3 (50.0) 5 (62.5) 
Combination of treatments** 3 (10.3) 6 (12.0) 9 (11.4) 3 (13.0) 3 (7.3) 7 (10.9) 0 (0.0) 1 (16.7) 1 (12.5) 
mIBG Therapy  0 (0.0) 1(2.0) 1(1.3) 0 (0.0) 1 (2.4) 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 
Other (e.g. Surgery or 
radiotherapy) 
1 (3.5) 5 (10.0) 6 (7.6) 1 (4.4) 3 (7.3) 4 (6.3) 0 (0.0) 1 (16.7) 1 (12.5) 
Phase I or II trials 0 (0.0) 3 (6.0) 3 (3.8) 0 (0.0) 3 (7.3) 3 (4.7) 0 (0.0) 0 (0.0) 0 (0.0) 
Palliative radiotherapy  15 (51.7) 10 (20.0) 25 (31.7) 0 (0.0) 4 (9.8) 4 (6.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Supportive care 0 (0.0) 4 (8.0) 4 (5.1) 11 (47.8) 8 (19.5) 19 (29.7) 0 (0.0) 1 (16.7) 1 (12.5) 
Total  29 (100) 50 (100) 79 (100) 23 (100) 41 (100) 64 (100) 2 (100) 6 (100) 8 (100) 
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Supplementary Table S4: Cox univariable analysis for post relapse overall 
survival time and relationship with clinical and biological variables for high risk 
cases  
 
Supplementary Table S3: Cox univariable analysis for post relapse overall 
survival time and relationship with clinical and biological variables for high risk 
cases  
 
Factor  N (%) Hazard ratio (95% CI) P-value  
Age at diagnosis 
>18 months   
 ≤18 months 
142 (89.3) 
17 (10.7) 
1 
1.15 (0.67 – 1.97) 
 
0.61 
Age at diagnosis 
≤ 5 years 
 > 5 years  
126 (79.3) 
33 (20.7) 
1 
0.62 (0.42 – 0.93) 
 
0.02 
Gender 
Males 
Females  
92 (57.9) 
67 (42.1) 
1 
1.14 (0.82 – 1.58) 
 
0.42 
Bone metastases at diagnosis 
 Yes 
 No   
110 (75.3) 
36 (24.7) 
1 
1.19 (0.80 – 1.76) 
 
0.39 
Bone marrow metastases at diagnosis 
 Yes  
 No     
120 (82.2) 
26 (17.8) 
1  
0.67 (0.42 – 1.06) 
 
0.08 
Liver metastases at diagnosis  
  No   
  Yes 
122 (87.8) 
17 (12.2) 
1 
1.95 (1.16 – 3.27) 
 
0.02 
Bone metastases at relapse 
   No   
  Yes 
70 (49.3) 
72 (50.7) 
1 
1.24 (0.88 – 1.74) 
 
0.23 
Bone marrow metastases at relapse 
  No   
  Yes 
58 (50.0) 
58 (50.0) 
  1 
0.86 (0.59 – 1.26) 
 
0.44 
MYCN  status 
  Not amplified 
  Amplified  
67 (57.8) 
49 (42.2) 
1 
2.10 (1.42 – 3.10) 
 
<0.001 
1p status 
  1p normal 
  1p deleted 
22 (38.6) 
35 (61.4) 
1 
1.58 (0.90 – 2.78) 
 
0.11 
MYCN  disease and 1p status  
MYCN  non amplified and 1p normal 
Either MYCN  amplified or 1p deleted 
MYCN  amplified and 1p deleted 
17 (31.5) 
8 (14.8) 
29 (53.7) 
1 
1.71 (0.71 – 4.11) 
2.11 (1.11 – 4.01) 
 
0.23 
0.02 
Time from diagnosis to relapse  
>24 months  
 18 – 24 months  
  12 – 18 months  
  6 – 12 months  
  < 6 months  
35 (22.0) 
28 (17.9) 
40 (25.2) 
32 (20.1) 
24 (15.1) 
1 
1.14 (0.68 – 1.92) 
1.24 (0.77 – 2.00) 
1.44 (0.87 – 2.38) 
1.82 (1.06 – 3.14) 
 
0.62 
0.37 
0.16 
0.03 
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Supplementary Table S5: Profile of survivors at the end of the study period  
(N = 16). 
 
Table 4: Profile of survivors at the end of the study period (N = 16) 
 
Characteristic  N (%, 95% CI) 
Gender   
    Male 
    Female  
10 (62.5, 38.6-81.5) 
6 (37.5, 18.5-61.4) 
Age at diagnosis (years)  
  Mean  
  Median  
  Range  
≤ 1 year  
2.9 
1.8 
0 – 12.8  
N = 7 
Age group  
  <18 months  
  ≥18 months   
8 (50.0, 28.0-72.0) 
8 (55.0, 28.0-72.0) 
Risk Group N = 15 
  High risk  
  Intermediate unresectable stage 3 non-MNA 
  Intemediate stage 4 non-MNA infants 
  Low risk  
5 (33.3, 15.2-58.3) 
4 (26.6, 10.9-52.0) 
4 (26.6, 10.9-52.0) 
2 (13.3, 3.7-37.9) 
Site of primary at diagnosis   
 Abdominal (includes adrenal and retroperitoneal) 
 Thoracic and spinal 
13 (81.3, 57.0-93.4) 
3 (18.7, 6.6-43.0) 
MYCN  status  N = 13  
  Amplified  
  Not amplified, MYCN  gain  
  Not amplified 
1 (7.7, 1.4-33.3) 
1 (7.7, 1.4-33.3) 
11 (84.6, 57.8-95.7) 
1p status N = 6 
  1p deleted 
  1p normal 
2 (33.3, 9.7-70.0) 
4 (66.6, 30.0-90.3) 
MYCN  disease and 1p status  N = 6  
MYCN  non amplified and 1p normal 
Either MYCN  amplified or 1p deleted or both 
4 (66.7, 30.0-90.3) 
2 (33.3, 9.7-70.0) 
INPC histology  N = 15 
  Unfavourable  
  Favourable  
11 (73.3, 48.0-89.1) 
4 (26.7, 10.9-51.6) 
Year of diagnosis   
≤ 2000 
>2000 
8 (50.0, 28.0-72.0) 
8 (50.0, 28.0-72.0) 
Overall response at end of treatment  N = 15 
 Stable disease  
 Mixed response  
 Partial response  
 Complete response  
 Progressive disease 
1 (6.7, 1.2-29.8) 
0 (0.0, 0-20.4) 
6 (40.0, 19.8-64.3) 
8 (53.3, 30.1-75.2) 
0 (0.0, 0-20.4) 
Time to relapse   
  Mean 
  Median  
  Inter-quartile range  
  Range 
22.4 months 
23.0 months  
8.1 – 35.4 months  
1.5 – 48.9 months  
Time from diagnosis to relapse   
< 6 months  
 6 – 18 months  
18 – 24 months  
>24 months 
4 (25.0, 10.2-49.5) 
2 (12.5, 3.5-36.0) 
2 (12.5, 3.5-36.0) 
8 (50.0, 28.0-72.0) 
* 95 % CI for proportions calculated using the Wilson score method.  
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Supplementary Table S6: Comparison of clinical characteristics of survivors 
with non-survivors of relapsed neuroblastoma. 
 
Supplementary Table S4: Comparison of clinical characteristics of survivors with non-
survivors of relapsed neuroblastoma. 
 
Characteristic  Non-Survivors 
N = 173 (%, 95% CI) α 
Survivors 
N = 16 (%, 95% CI) β 
P-value 
Gender     
    Male 
    Female  
99 (57.2, 49.5-64.7) 
74 (42.8, 35.3-50.5) 
10 (62.5, 38.6-81.5) 
6 (37.5, 18.5-61.4) 
 
0.45 
Age at diagnosis (years)    
  Mean  
  Median  
  Range  
≤ 1 year  
4.2 
3.1 
0-19.5 
N=7 
2.9 
1.8 
0 – 12.8 
N = 7 
 
 
0.02* 
Age group    
  <18 months  
  ≥18 months   
20 (11.6, 7.2-17.3) 
153 (88.4, 82.7-92.8) 
8 (50.0, 28.0-72.0) 
8 (55.0, 28.0-72.0) 
 
<0.001 
INPC histology  N = 138 N = 15  
  Unfavourable  
  Favourable 
133 (96.4, 91.7-98.8) 
5 (3.6, 1.2-8.3) 
11 (73.3, 48.0-89.1) 
4 (26.7, 10.9-51.6) 
 
0.006 
Time to relapse     
  Mean 
  Median  
  Inter-quartile range  
  Range 
17.7 months 
14.37 months 
9.2 – 21.0 months 
1.3 – 96.2 months 
22.4 months 
23.0 months 
8.1 – 35.4 months 
1.5 – 48.9 months 
 
0.14 
Time from diagnosis to relapse     
< 6 months  
 6 – 18 months  
18 – 24 months  
>24 months 
28 (16.2, 11.0-22.5) 
79 (45.7, 38.1-53.4) 
30 (17.3, 12.0-23.8) 
36 (20.8, 15.0-27.6) 
4 (25.0, 10.2-49.5) 
2 (12.5, 3.5-36.0) 
2 (12.5, 3.5-36.0) 
8 (50.0, 28.0-72.0) 
 
0.01 
Overall response at end of 1st line 
treatment  
N = 151 
 
N = 15 
 
 
Stable disease  
 Mixed response  
 Partial response  
 Complete response  
 Progressive disease 
6 (4.0, 1.3-7.4) 
12 (8.0, 3.6-11.8) 
76 (50.3, 36.4-51.7) 
32 (21.2, 13.0-25.1) 
25 (16.6, 9.6-20.6) 
1 (6.7, 1.2-29.8) 
0 (0.0, 0-20.4) 
6 (40.0, 19.8-64.3) 
8 (53.3, 30.1-75.2) 
0 (0.0, 0-20.4) 
 
 
0.04 
  
* Comparison of medians of the 2 groups using the two-sample Wilcoxon rank-sum (Mann-
Whitney) test. . α 95% CI were calculated for percentages using the asymptotic method. β 95% 
CI for proportions were calculated using the Wilson score method.  
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Figure 1: Flow diagram showing numbers of cases included in the study.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All relapsed neuroblastoma 
cases identified from 4 CCLG 
centres in UK  
n = 198 
Cases that died within 7 days of diagnosis of 
relapse were excluded from the study  
N = 9 
All relapsed neuroblastoma cases 
excluding those who died within 7 days of 
diagnosis of relapse  
N = 189 
High Risk cases  
N = 159  
Intermediate Risk  
N = 24 
 
 
Low risk (stage 1, 2 & 4s) 
N = 3 
Risk unknown 
(stage unknown) 
N = 3 
Stage 4, MYCN non-amplified 
infants <12 months 
N = 7 
Died  
N = 154 
Survived  
N = 5 
Unresectable, stage 3, MYCN non-
amplified  
N = 17 
Died  
N = 1 
Survived 
N = 2 
Died  
N = 3 
Survived 
N = 4 
Died  
N = 13 
Survived 
N = 4 
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Figure 2: Kaplan Meier graphs for post relapse overall survival time for 
the high risk group (N = 159). 
Figure 2a: Post relapse overall survival (PROS) time 
 
Median PROS time for high risk cases was 4.5 
months (IQR = 1.9 – 11.4). 5 year PROS for high risk 
cases was 7.4% (95% CI 4.0-12.1%). 
Figure 2b: Post relapse overall survival by year of 
diagnosis 
 
Median PROS time was 2.9 months (IQR 1.4 – 6.9) for 
cases diagnosed ≤ 2000 versus 8.4 months (IQR 3.0 – 
17.4) for cases diagnosed > 2000 (P <0.001). 5 year 
PROS for high risk cases diagnosed ≤ 2000 was 2.4% 
(95% CI 0.5-7.7%) versus 12.7% (95% CI 6.4-21.2%) 
for cases diagnosed >2000. 
Figure 2c: PROS by MYCN status 
Median PROS time was 2.9 months (95% CI 2.0 – 
4.3) for MYCN amplified versus 8.5 months for MYCN 
non-amplified (95% CI 5.9 –11.1) (P < 0.001). ). 5 year 
PROS for MYCN non-amplified cases was 9.0% (95% 
CI 3.7-17.2%) versus 4.1% (95% CI 0.8-12.3%) for 
MYCN amplified cases.j 
Figure 2d: PROS for cases diagnosed  ≤ 2000 by 
MYCN status  
 
For cases diagnosed ≤ 2000, the median PROS for 
MYCN amplified disease was 1.5 months (95% CI 0.9 
– 2.7) versus 5.1 months (95% CI 2.9 – 7.9) for MYCN 
non-amplified (P < 0.001). 5 year PROS for MYCN 
non-amplified cases was 3.6% (95% CI 0.3-15.4%) 
versus 0% for MYCN amplified cases. 
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Figure 2e: PROS for cases diagnosed  > 2000 by MYCN  status 
 
For cases diagnosed > 2000, the median PROS for MYCN amplified disease was 4.3 months (95% CI 2.9 – 
6.6) versus 10.9 months (95% CI 6.3 – 14.4) for MYCN non-amplified (P= 0.02). 5 year PROS for MYCN non-
amplified cases was 12.8% (95% CI 4.7-25.2%) versus 7.7% (95% CI 1.3-21.7%) for MYCN amplified cases. 
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Figure 3: Flow diagram showing treatments high risk patients received at first relapse and its outcome. 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
High Risk relapsed neuroblastoma cases (N = 159) 
Cases diagnosed ≤ 2000 (N=82) Cases diagnosed > 2000 (N=76) 
Median PRPFS 
in months (IQR)  
Median PRPFS 
in months (IQR) 
Median PROS 
in months (IQR)  
Treatments at 
relapse  
Median PROS 
in months (IQR)  
N = 16 
2.1 (1.3 – 2.2) 
N = 7 
6.7 (3.5 - 29.5) 
N = 22 
3.8 (2.1 – 9.7) 
Second line 
chemotherapy 
N = 29 
6.6 (2.5 – 17.5) 
N = 7 
6.1 (2.6 - 7.1) 
N = 5  
4.9 (2.8 – 8.7) 
N = 10 
4.4 (2.0 – 7.5) 
Combination of 
treatments 
N = 12  
8.5 (4.3 – 12.3)  
N = 4 
6.5 (3.2 – 8.8) 
N < 3 
--  
N < 3 
-- 
mIBG therapy N = 6  
12.2 (10.9 - 26.2) 
N = 4  
4.7 (2.6 – 10.6) 
N <3  
-- 
N = 4  
4.2 (1.8 – 6.9) 
Other 
treatment e.g. 
surgery  
N = 8  
11.3 (5.9 – 37.9) 
N = 4  
3.2 (1.6 – 6.2) 
N = 3  
1.7 (1.4 – 16.0) 
N = 5  
5.1 (4.2 – 22.6) 
Phase I or II 
trials 
N = 5 
13.5 (7.7 – 16.4) 
N < 3  
N = 3  
3.4 (2.2 – 5.1) 
N = 10 
2.1 (1.9 – 4.7) 
Palliative 
radiotherapy  
N =6 
8.6 (4.2 – 13.3) 
N < 3 
-- 
N < 3 
-- 
N = 12  
0.9 (0.4 - 1.7) 
Supportive 
care 
N =8  
1.5 (0.6 – 2.9) 
43 
 
PROS is post relapse overall survival.               IQR is interquartile range.                                                                                                                                                                                                                                                    
PRPFS is post relapse progression free survival.  
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Supplementary Figure S1: Kaplan Meier graphs for overall survival time 
and post relapse overall survival time for all relapsed neuroblastoma 
cases by year of diagnosis (N=189).  
 
Figure S1a: Overall survival (OS) time from diagnosis 
by year of diagnosis 
 
Median OS time was 21.3 months (IQR 12.4 – 30.6 
months) for cases diagnosed ≤ 2000 versus 26.8 
months (IQR 15.9 – 49.5) for cases diagnosed > 2000 
(P = 0.02). 5 year OS time was 13% (95% CI 7–20) for 
cases diagnosed ≤ 2000. 5 year OS time was 22% 
(95% CI 14 - 31) for cases diagnosed >2000. 
Figure S1b: Post relapse overall survival (PROS) by 
year of diagnosis. 
 
Median PROS time was 3.5 months (IQR 1.5 – 9.3 
months) for cases diagnosed ≤ 2000 versus 9.4 
months (IQR 3.5 – 26.2) for cases diagnosed > 2000 
(P = 0.001). 5 year PROS time was 9% (95% CI 4 - 
16) for cases diagnosed ≤ 2000. 5 year PROS time 
was 17% (95% CI 10 - 25) for cases diagnosed >2000. 
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Supplementary Figure S2: Kaplan Meier graphs for overall survival time 
for the high risk group (N = 159). 
 
Figure S2a: Overall survival (OS) time from diagnosis 
 
Median OS time for high risk cases was 22.7 months 
(inter-quartile range 13.5 – 33.8 months). 5 year OS 
9.9% (95% CI 5.9-15.2%).  
 Figure S2b: Overall survival time by year of diagnosis 
 
Median OS time was 20.2 months (IQR 12.4 – 29.2 
months) for cases diagnosed ≤ 2000 versus 26.1 
months (IQR 15.4 – 43.4) for cases diagnosed > 2000 
(P = 0.001). 5 year OS for high risk cases diagnosed ≤ 
2000 was 4.9% (95% CI 1.6-11.1%) versus 15.2% 
(95% CI 8.2-24.2%) for cases diagnosed >2000. 
Figure S2c: Overall survival time by MYCN status 
 
Median OS time was 16.1 months (95% CI 13.9 – 19.5 months) for MYCN  amplified versus 26.8 months (95% 
CI 22.7 – 30.6 months) for non-MYCN  amplified (P = 0.001). 5 year PROS for MYCN non-amplified cases was 
13.4% (95% CI 6.6-22.7%) versus 6.1% (95% CI 1.6-15.2%) for MYCN amplified cases. 
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Supplementary Figure S3: Kaplan Meier graphs for overall survival time 
and post relapse overall survival time for the intermediate risk, 
unresectable non-MNA risk group (N = 17).  
 
Figure S3a: Overall survival time from diagnosis  
 
Median OS time for the intermediate, stage 3 
unresectable MYCN non-amplified cases was 72.9 
months (inter-quartile range 19.5 – 99.0 months). The 
5 year OS was 53% (95% CI 28 - 73). 
Figure S3b: Post relapse overall survival time 
 
Median PROS time for the intermediate, stage 3 
unresectable MYCN non-amplified cases was 11.8 
months (inter-quartile range 9.0 – 51.6 months). The 5 
year PROS was 24% (95% CI 7 - 45). 
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